[Combination of ketamine and esketamine with Exposure and Response Prevention (ERP) therapy for Obsessive-Compulsive Disorder].
Combinaison de la kétamine et de l’eskétamine avec la thérapie d’exposition avec prévention de la réponse (EPR) dans le trouble obsessionnel-compulsif.
EPR
ERP
Exposition avec prévention de la réponse
Exposure and response prevention psychotherapy
Extinction de la peur
Fear extinction
Ketamine
Kétamine
NMDA receptor
OCD
Obsessional-compulsive Disorder
Récepteur NMDA
TOC
Trouble obsessionnel compulsif
Journal
L'Encephale
ISSN: 0013-7006
Titre abrégé: Encephale
Pays: France
ID NLM: 7505643
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
30
06
2021
revised:
24
07
2022
accepted:
04
08
2022
medline:
22
5
2023
pubmed:
25
4
2023
entrez:
24
04
2023
Statut:
ppublish
Résumé
Obsessive-Compulsive Disorder (OCD), characterized by the combination of obsession and compulsion, is a clinical and therapeutic challenge. Many patients with OCD do not respond to first-line treatments such as serotonin selective reuptake inhibitors (SSRIs) and exposure and response prevention psychotherapy (ERP). For these resistant patients, some preliminary studies have shown that ketamine, a non-selective glutamatergic NMDA receptors antagonist, could improve the obsessive symptoms. A number of these studies have also suggested that the combination of ketamine with ERP psychotherapy may jointly potentiate the effectiveness of ketamine and ERP. In this paper, we present the existing data on the combined use of ketamine with ERP psychotherapy for OCD. We suggest that modulation of NMDA receptor activity and glutamatergic signaling by ketamine may promote the therapeutic mechanisms involved in ERP such as fear extinction and brain plasticity mechanisms. Finally, we propose a ketamine-augmented ERP psychotherapy (KAP-ERP) protocol in OCD, and we present the limitations associated with its application in clinical practice.
Identifiants
pubmed: 37095049
pii: S0013-7006(22)00180-4
doi: 10.1016/j.encep.2022.08.011
pii:
doi:
Substances chimiques
Esketamine
50LFG02TXD
Ketamine
690G0D6V8H
Types de publication
English Abstract
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
304-311Informations de copyright
Copyright © 2022 L'Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.